{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T12:40:25Z","timestamp":1710074425624},"reference-count":0,"publisher":"Tunisian Society of Medical Sciences","issue":"3","license":[{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tunis Med"],"abstract":"<jats:p>Introduction\u00a0: L'impact des m\u00e9dicaments antiviraux \u00e0 action directe (AAD) sur les manifestations extra-h\u00e9patiques de l'h\u00e9patite C chronique (HCC) est peu \u00e9tudi\u00e9.\nObjectif : Evaluer la pr\u00e9valence de l'ath\u00e9roscl\u00e9rose subclinique chez les patients atteints de HCC et l'impact des AAD sur les l\u00e9sions ath\u00e9roscl\u00e9rotiques.\nM\u00e9thodes : Une \u00e9tude \u00e9valuative prospective de 5 ans a \u00e9t\u00e9 men\u00e9e, incluant les patients suivis pour une HCC. L'ath\u00e9roscl\u00e9rose subclinique a \u00e9t\u00e9 \u00e9valu\u00e9e par la mesure \u00e9chographique de l'\u00e9paisseur intima-m\u00e9dia carotidienne (IMTc), et les mesures IMTc les plus \u00e9lev\u00e9es ont d\u00e9fini l'IMTc maximum (IMTc max). Une IMTc &gt;75e percentile (IMTc75) a \u00e9t\u00e9 d\u00e9finie comme une ath\u00e9roscl\u00e9rose subclinique \u00e0 haut risque cardiovasculaire. Les patients ont \u00e9t\u00e9 \u00e9valu\u00e9s avant (T0) et un an apr\u00e8s la r\u00e9alisation de la th\u00e9rapie par les AAD (T1).\nR\u00e9sultats : Au moment T0, quarante patients (\u00e2ge m\u00e9dian : 55 ans ; ratio homme\/femme = 0,48) ont \u00e9t\u00e9 inclus. La valeur moyenne de l'IMTc max \u00e9tait de 0,68 \u00b1 0,16 mm. Une ath\u00e9roscl\u00e9rose subclinique a \u00e9t\u00e9 observ\u00e9e chez 82,5 % des patients. Une r\u00e9ponse virologique soutenue (RVS) est obtenue. Par rapport au moment T0, il y a eu une augmentation significative des taux de cholest\u00e9rol et de triglyc\u00e9rides. L'IMTc max \u00e9tait significativement plus \u00e9lev\u00e9e au moment T1 par rapport \u00e0 T0. La pr\u00e9valence de l'IMTc75 \u00e9tait de 82,1 % au moment T0 et de 75 % au moment T1 (p = 0,5).\nConclusions : La RVS chez les patients atteints de HCC trait\u00e9s par AAD \u00e9tait associ\u00e9e \u00e0 une aggravation des l\u00e9sions ath\u00e9roscl\u00e9rotiques carotidiennes.<\/jats:p>","DOI":"10.62438\/tunismed.v102i3.4601","type":"journal-article","created":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T12:18:22Z","timestamp":1710073102000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact des antiviraux \u00e0 action directe sur l'ath\u00e9roscl\u00e9rose subclinique chez les patients atteints d\u2019une h\u00e9patite C chronique"],"prefix":"10.62438","volume":"102","author":[{"given":"Sarra","family":"Laabidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna","family":"Medhioub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal","family":"Khsiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Bach Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Ben Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamine","family":"Hamzaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"31112","published-online":{"date-parts":[[2024,3,10]]},"container-title":["La Tunisie M\u00e9dicale"],"original-title":[],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T12:18:23Z","timestamp":1710073103000},"score":1,"resource":{"primary":{"URL":"https:\/\/latunisiemedicale.com\/index.php\/tunismed\/article\/view\/4601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,10]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,10]]}},"URL":"https:\/\/doi.org\/10.62438\/tunismed.v102i3.4601","relation":{},"ISSN":["2724-7031","0041-4131"],"issn-type":[{"value":"2724-7031","type":"electronic"},{"value":"0041-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,10]]}}}